Jun Mm Qiu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jun Mm Qiu has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Furen Zeng
Department of Oncology, Hunan Provincial People’s Hospital (The First Affiliated Hospital of Hunan Normal University), Changsha, China
1 shared publication - Qiaoyuan Wu
Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, China
1 shared publication - Shengying Mm Xiao
Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi 530021, P.R. China
1 shared publication - Shixiong Liang
Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, China
1 shared publication - Xiao-Dong Zhu
Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, People’s Republic of China
1 shared publication Xinpan Li
Department of Oncology, Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University), Changsha, Hunan 410006, PR China
1 shared publication
Latest Publications
- 16 January 2026
- Published by Elsevier in Tissue and Cell
- Vol. 100, 103330
Integrative multi-omics profiling implicates purine metabolism and the PI3K-Akt pathway in radiation-induced lung injury
- 16 January 2026
- Published by Elsevier in Tissue and Cell
- Vol. 100, 103330
Integrative multi-omics profiling implicates purine metabolism and the PI3K-Akt pathway in radiation-induced lung injury
- Open Access
- 15 July 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (28) , e29391
Identification of a pyroptosis-related prognosis gene signature and its relationship with an immune microenvironment in gliomas
Background: Glioma is the most common type of primary brain cancer, and the prognosis of most patients with glioma is poor. Pyroptosis is a newly discovered inflammatory programmed cell death. However, the expression of pyroptosis-related genes (PRGs) in glioma and its correlation with prognosis are unclear. Methods: 27 pyroptosis genes differentially expressed between glioma and adjacent normal tissues were identified. All glioma cases could be stratified into 2 subtypes based on these differentially expressed PRGs. The prognostic value of each PRG was evaluated to construct a prognostic model. Results: A novel 16-gene signature was constructed by using the least absolute shrinkage and selection operator Cox regression method. Then, patients with glioma were divided into low- and high-risk groups in the TCGA cohort. The survival rate of patients in the low-risk group was significantly higher than that in the high-risk group (P = .001). Patients with glioma from the Gene Expression Omnibus (GEO) cohort were stratified into 2 risk groups by using the median risk score. The overall survival (OS) of the low-risk group was longer than that of the high-risk group (P = .001). The risk score was considered an independent prognostic factor of the OS of patients with glioma. Gene ontology and Kyoto Encylopedia of Genes and Genomes analysis showed that the differentially expressed PRGs were mainly related to neutrophil activation involved in immune responses, focal adhesion, cell cycle, and p53 signaling pathway. Conclusion: PRGs could predict the prognosis of glioma and play significant roles in a tumor immune microenvironment.
- 15 July 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (28) , e29391
Open AccessIdentification of a pyroptosis-related prognosis gene signature and its relationship with an immune microenvironment in gliomas
Background: Glioma is the most common type of primary brain cancer, and the prognosis of most patients with glioma is poor. Pyroptosis is a newly discovered inflammatory programmed cell death. However, the expression of pyroptosis-related genes (PRGs) in glioma and its correlation with prognosis are unclear. Methods: 27 pyroptosis genes differentially expressed between glioma and adjacent normal tissues were identified. All glioma cases could be stratified into 2 subtypes based on these differentially expressed PRGs. The prognostic value of each PRG was evaluated to construct a prognostic model. Results: A novel 16-gene signature was constructed by using the least absolute shrinkage and selection operator Cox regression method. Then, patients with glioma were divided into low- and high-risk groups in the TCGA cohort. The survival rate of patients in the low-risk group was significantly higher than that in the high-risk group (P = .001). Patients with glioma from the Gene Expression Omnibus (GEO) cohort were stratified into 2 risk groups by using the median risk score. The overall survival (OS) of the low-risk group was longer than that of the high-risk group (P = .001). The risk score was considered an independent prognostic factor of the OS of patients with glioma. Gene ontology and Kyoto Encylopedia of Genes and Genomes analysis showed that the differentially expressed PRGs were mainly related to neutrophil activation involved in immune responses, focal adhesion, cell cycle, and p53 signaling pathway. Conclusion: PRGs could predict the prognosis of glioma and play significant roles in a tumor immune microenvironment.